Solaris Resources (CVE:SLS) Downgraded by Maxim Group to “Hold”

Solaris Resources (CVE:SLS) was downgraded by stock analysts at Maxim Group from a “strong-buy” rating to a “hold” rating in a research note issued on Tuesday,Zacks.com reports.

Solaris Resources Stock Performance

Solaris Resources stock opened at C$6.15 on Tuesday. Solaris Resources has a 12 month low of C$1.38 and a 12 month high of C$7.09. The stock’s 50-day moving average is C$6.15 and its 200-day moving average is C$6.15.

Solaris Resources Company Profile

SELLAS Life Sciences Group, Inc, a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer.